(S)-4-benzyl-3-((3S,4R)-1-benzyl-4-(4-chlorophenyl)pyrrolidine-3-carbonyl)oxazolidin-2-one | 862283-67-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (S)-4-benzyl-3-((3S,4R)-1-benzyl-4-(4-chlorophenyl)pyrrolidine-3-carbonyl)oxazolidin-2-one
• 英文别名: (4S)-4-benzyl-3-{[(3S,4R)-1-benzyl-4-(4-chlorophenyl)pyrrolidin-3-yl]carbonyl}-1,3-oxazolidin-2-one；(4S)-4-benzyl-3-[(3S,4R)-1-benzyl-4-(4-chlorophenyl)pyrrolidine-3-carbonyl]-1,3-oxazolidin-2-one
• CAS: 862283-67-8
• 化学式: C₂₈H₂₇ClN₂O₃
• 分子量: 474.987
• InChiKey: LAAIQSQLPMJDMD-KKUQBAQOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  34
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  49.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (S)-4-benzyl-3-((3S,4R)-1-benzyl-4-(4-chlorophenyl)pyrrolidine-3-carbonyl)oxazolidin-2-one 、 碳酸二甲酯 在 sodium methylate 作用下， 以 二氯甲烷 为溶剂， 反应 24.0h， 以79%的产率得到(3S,4R)-methyl 1-benzyl-4-(4-chlorophenyl)pyrrolidine-3-carboxylate
  参考文献：
  名称：

  Pharmaceutically active compounds

  摘要：

  本发明涉及一类通式（I）所示的黑素皮质素MCR4激动剂，其中R1、R2、R3、R4和R5如本文所定义，特别涉及选择性MCR4激动剂化合物，它们在医学上的应用，含有它们的组合物，用于它们制备的工艺以及用于这些工艺的中间体。

  公开号：

  US20050176772A1
• 作为产物：
  描述：

  (2E)-3-(4-氯苯基)丙烯酰氯 在 三乙胺 、 三氟乙酸 、 lithium chloride 作用下， 以 二氯甲烷 为溶剂， 反应 24.25h， 生成 (S)-4-benzyl-3-((3S,4R)-1-benzyl-4-(4-chlorophenyl)pyrrolidine-3-carbonyl)oxazolidin-2-one
  参考文献：
  名称：

  Structure-Based Design of Potent and Selective Leishmania N-Myristoyltransferase Inhibitors

  摘要：

  Inhibitors of Leishmania N-myristoyltransferase (NMT), a potential target for the treatment of leishmaniasis, obtained from a high-throughput screen, were resynthesized to validate activity. Crystal structures bound to Leishmania major NMT were obtained, and the active diastereoisomer of one of the inhibitors was identified. On the basis of structural insights, enzyme inhibition was increased 40-fold through hybridization of two distinct binding modes, resulting in novel, highly potent Leishmania donovani NMT inhibitors with good selectivity over the human enzyme.

  DOI：

  10.1021/jm5011397

文献信息

• (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
  申请人：Pfizer Inc

  公开号：US07649002B2

  公开（公告）日：2010-01-19

  The present invention relates to a class of melanocortin MCR4 agonists of general formula (I) wherein R1, R2, R3, R4 and R5 are as defined herein and especially to selective MCR4 agonist compounds, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes.

  本发明涉及一类黑素细胞激素MCR4激动剂，其一般式为（I），其中R1、R2、R3、R4和R5如本文所定义，特别是选择性MCR4激动剂化合物，它们在医学上的使用，包含它们的组合物，制备它们的过程以及用于这种过程的中间体。
• PIPERIDINYLCARBONYL-PYRROLIDINES AND THEIR USE AS MELANOCORTIN AGONISTS
  申请人：Pfizer Limited

  公开号：EP1716135A1

  公开（公告）日：2006-11-02
• US7649002B2
  申请人：——

  公开号：US7649002B2

  公开（公告）日：2010-01-19
• [EN] PIPERIDINYLCARBONYL-PYRROLIDINES AND THEIR USE AS MELANOCORTIN AGONISTS<br/>[FR] PIPERIDINYLCARBONYL-PYRROLIDINES ET LEUR UTILISATION EN TANT QU'AGONISTES DE LA MELANOCORTINE
  申请人：PFIZER LTD

  公开号：WO2005077935A1

  公开（公告）日：2005-08-25

  The present invention relates to a class of melanocortin MCR4 agonists of general formula (I) wherein R', R2, R3, R4 and R5 are as defined herein and especially to selective MCR4 agonist compounds, tot heir use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes.
• Structure-Based Design of Potent and Selective <i>Leishmania</i> <i>N</i>-Myristoyltransferase Inhibitors
  作者：Jennie A. Hutton、Victor Goncalves、James A. Brannigan、Daniel Paape、Megan H. Wright、Thomas M. Waugh、Shirley M. Roberts、Andrew S. Bell、Anthony J. Wilkinson、Deborah F. Smith、Robin J. Leatherbarrow、Edward W. Tate

  DOI：10.1021/jm5011397

  日期：2014.10.23

  Inhibitors of Leishmania N-myristoyltransferase (NMT), a potential target for the treatment of leishmaniasis, obtained from a high-throughput screen, were resynthesized to validate activity. Crystal structures bound to Leishmania major NMT were obtained, and the active diastereoisomer of one of the inhibitors was identified. On the basis of structural insights, enzyme inhibition was increased 40-fold through hybridization of two distinct binding modes, resulting in novel, highly potent Leishmania donovani NMT inhibitors with good selectivity over the human enzyme.